Synthetic method for sotagliflozin and its analogues

Abstract

The invention discloses a synthetic method for sotagliflozin and its analogues. The method comprises the following steps: with dapagliflozin acetate 1 as a raw material, carrying out oxidation so as to obtain diaryl ketone 2; selectively removing an acetyl group in the compound 2 so as to obtain primary alconol 3; carrying out dehydroxymethyl fluorination so as to obtain fluoroglucoside 4; then subjecting a carbonyl group to reductive alkylation so as to obtain a compound 5; reacting an activated C-F bond and a nucleophilic reagent to obtain a glycosylation product 6a-6c; and finally removingan acetyl group so as to obtain sotagliflozin and its analogue 7a-7c, or subjecting the compound 5 to removal of the acetyl group to obtain a sotagliflozin analogue 7d. The synthetic method of the invention has the following advantages: the raw material dapagliflozin acetate can be prepared from inexpensive and easily available 1,5-gluconolactone; only the acetyl group is used as a protecting group which can be removed under mild conditions; a reducing agent sodium borohydride used in the method is cheap, easily available, and stable in water and air; stereoselective reduction is not involved,so the difficulty of synthesis is lowered, experimental operation is simplified, and the method is suitable for large-scale preparation.

Description

technical field [0001] The invention belongs to the field of drug synthesis, and in particular relates to a chemical synthesis method of sotagliflozin and its analogues. technical background [0002] Diabetes mellitus is a progressive disorder characterized by hyperglycemia in carbohydrate, protein, and fat metabolism. It is mainly divided into two types: type I diabetes and type II diabetes. According to the data released by the International Diabetes Federation (IDF), the number of diabetic patients (20-79 years old) in the world has reached 382 million in 2013, and this value will increase to 592 million in 2035 for the treatment of diabetes In 2013, the expenditures on diabetes and complications reached 548 billion U.S. dollars, accounting for 11% of the world's total expenditure on adult health care, and this value will increase to 627 billion U.S. dollars in 2035 (International Diabetes Federation. Diabetes Atlas, 6th ed.). [0003] The sodium-glucose cotransporters ...

AI Technical Summary

Problems solved by technology

[0007] The problems that above-mentioned these synthetic methods exist are: (1) use expensive rare L-xylose as raw material; (3) the aryl metal reagent generated by 4-iodo-1-chloro-2-(4-ethoxybenzyl)benzene no matter with aldehyde 9 addition , or react with Weinreb amine 11 to generate ketone 12, and then use a reducing agent such as Red-Al to reduce the stereoselectivity of alcohol 10 is not high; (4) the used reducing agent Red-Al is sensitive to water and air, so it needs Severe reaction conditions; (5) Use bromoglycoside 13 with low stability as a glycosidation donor; (6) Removal of large sterically hindered pivaloyl (Piv) requires strong reaction conditions

These deficiencies make the existing synthetic route of soxagliflozin costly, which is unfavorable for its large-scale preparation

Images